公开(公告)号：US20240148967A1

公开(公告)日：2024-05-09

申请号：US18104979

申请日：2023-02-02

申请人： Pacira Pharmaceuticals, Inc.

发明人： Roy Winston ,  Mary DiGiorgi

IPC分类号： A61M5/158 ,  A61K9/00 ,  A61K9/127 ,  A61K31/445 ,  A61M5/42 ,  A61P23/02

CPC分类号： A61M5/158 ,  A61K9/0085 ,  A61K9/127 ,  A61K31/445 ,  A61M5/427 ,  A61P23/02

摘要： In some embodiments provided herein are methods of administering an adductor canal block in a patient, wherein the methods include: (a) selecting an entry point of an injection needle in a leg of the patient; (b) inserting the injection needle into the leg of the patient at the entry point; (c) identifying a first nerve in the leg of the patient; (d) administering to the first nerve saline and a pharmaceutical composition; (e) identifying a second nerve in the leg of the patient; (f) administering to the second nerve saline and the pharmaceutical composition; wherein the first nerve and second nerve are selected from the group consisting of the nerve to vastus medialis (NVM) and the saphenous nerve, and wherein the first nerve is not the second nerve, and wherein the pharmaceutical composition comprises multivesicular liposomes.

公开(公告)号：US20240139237A1

公开(公告)日：2024-05-02

申请号：US18376044

申请日：2023-10-03

申请人： Nicholas L. Abbott ,  Jonathan F. McAnulty

发明人： Nicholas L. Abbott ,  Jonathan F. McAnulty

IPC分类号： A61K33/38 ,  A61K9/70 ,  A61K31/167 ,  A61K31/381 ,  A61K31/445 ,  A61K33/24 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61L15/28 ,  A61L15/44 ,  A61P17/02 ,  A61P31/02

CPC分类号： A61K33/38 ,  A61K9/7092 ,  A61K31/167 ,  A61K31/381 ,  A61K31/445 ,  A61K33/24 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61L15/28 ,  A61L15/44 ,  A61P17/02 ,  A61P31/02 ,  A61L2300/404 ,  A61L2300/61

摘要： The present invention relates to large scale manufacture of nanoscale microsheets for use in applications such as wound healing or modification of a biological or medical surface.

公开(公告)号：US20240139172A1

公开(公告)日：2024-05-02

申请号：US18477753

申请日：2023-09-29

申请人： NeuroPn Therapeutics, Inc.

发明人： Ish Khanna ,  Sivaram Pillarisetti ,  Hans Marcus Malkmus ,  Kathrin Christin Kortschak

IPC分类号： A61K31/4545 ,  A61K31/27 ,  A61K31/445 ,  A61K31/454 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K31/4545 ,  A61K31/27 ,  A61K31/445 ,  A61K31/454 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K39/3955 ,  A61P35/00

摘要： Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of cancer as a monotherapy or a combination therapy with chemotherapeutic agents and/or checkpoint inhibitors.

公开(公告)号：US11964017B2

公开(公告)日：2024-04-23

申请号：US18487887

申请日：2023-10-16

申请人： The General Hospital Corporation

发明人： Lilit Garibyan ,  Richard Rox Anderson ,  William A. Farinelli ,  Emilia Javorsky

IPC分类号： A61K45/06 ,  A61K9/00 ,  A61K31/045 ,  A61K31/047 ,  A61K31/137 ,  A61K31/167 ,  A61K31/245 ,  A61K31/445 ,  A61K31/7004 ,  A61K31/718 ,  A61K31/765 ,  A61K33/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/28

CPC分类号： A61K45/06 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/045 ,  A61K31/047 ,  A61K31/137 ,  A61K31/167 ,  A61K31/245 ,  A61K31/445 ,  A61K31/7004 ,  A61K31/718 ,  A61K31/765 ,  A61K33/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/28

摘要： Described herein are compositions comprising, and methods for using, biocompatible cold slurries and methods of administering the same to provide reversible inhibition of peripheral nerves in a subject in need thereof.

公开(公告)号：US11958852B2

公开(公告)日：2024-04-16

申请号：US17405736

申请日：2021-08-18

申请人： INTRA-CELLULAR THERAPIES, INC.

发明人： Sharon Mates ,  Robert Davis ,  Kimberly Vanover ,  Lawrence Wennogle

IPC分类号： A61K31/4985 ,  A61K31/445 ,  A61K31/5383 ,  A61K45/06 ,  A61P25/28 ,  C07D471/14 ,  C07D471/16

CPC分类号： C07D471/14 ,  A61K31/445 ,  A61K31/4985 ,  A61K31/5383 ,  A61K45/06 ,  A61P25/28 ,  C07D471/16 ,  A61K31/4985 ,  A61K2300/00 ,  A61K31/5383 ,  A61K2300/00

摘要： The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.

公开(公告)号：US20240115708A1

公开(公告)日：2024-04-11

申请号：US18222745

申请日：2023-07-17

申请人： Amicus Therapeutics, Inc.

发明人： Douglas Stuart Greene ,  Kenneth Valenzano

IPC分类号： A61K47/22 ,  A61K31/445 ,  A61K38/47

CPC分类号： A61K47/22 ,  A61K31/445 ,  A61K38/47

摘要： The presently disclosed subject matter provides a formulation for the use of 1-deoxygalactonojirimycin and/or enzyme replacement therapy for the treatment of Fabry disease.

公开(公告)号：US11952588B2

公开(公告)日：2024-04-09

申请号：US16967375

申请日：2019-02-07

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Everett H. Meyer ,  Robert S. Negrin

IPC分类号： A61K35/17 ,  A61K31/436 ,  A61K31/445 ,  A61K35/28 ,  A61K39/00 ,  A61P35/02 ,  A61P37/06 ,  C12N5/0783 ,  C12N5/0789 ,  A61K35/12

CPC分类号： C12N5/0647 ,  A61K31/436 ,  A61K31/445 ,  A61K35/17 ,  A61K35/28 ,  A61K39/001 ,  A61P35/02 ,  A61P37/06 ,  C12N5/0637 ,  A61K2035/122 ,  C12N2506/11

摘要： The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.

公开(公告)号：US20240109874A1

公开(公告)日：2024-04-04

申请号：US18504741

申请日：2023-11-08

申请人： Takeda Pharmaceutical Company Limited

发明人： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC分类号： C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04

CPC分类号： C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof.




wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20240108728A1

公开(公告)日：2024-04-04

申请号：US18278416

申请日：2022-08-24

申请人： ANHUI UNIVERSITY

发明人： Rupei TANG ,  Guoqing YAN ,  Xin WANG

IPC分类号： A61K47/22 ,  A61K31/337 ,  A61K31/415 ,  A61K31/4184 ,  A61K31/445 ,  A61K38/28 ,  A61K38/38 ,  A61K47/34 ,  C07D317/34

CPC分类号： A61K47/22 ,  A61K31/337 ,  A61K31/415 ,  A61K31/4184 ,  A61K31/445 ,  A61K38/28 ,  A61K38/38 ,  A61K47/34 ,  C07D317/34

摘要： An improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, a preparation method thereof, and a topical sustained release drug delivery formulation including the same are provided. The improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant is obtained by mixing methoxy-free orthoester compounds (classes I and II) in different proportions or mixing an orthoester compound (class I or II) with a biocompatible medical polymer material in different proportions, where an orthoester compound of class I has a chemical formula shown in formula I:




and an orthoester compound of class II has a chemical formula shown in formula II:




The present disclosure has the following beneficial effects: In the present disclosure, the biosafety of the pharmaceutical adjuvant is improved by adjusting a substituent type and a length of an orthoester compound, and the properties of the orthoester mixture pharmaceutical adjuvant do not change before and after the improvement.

公开(公告)号：US20240075052A1

公开(公告)日：2024-03-07

申请号：US18476506

申请日：2023-09-28

申请人： Alnylam Pharmaceuticals, Inc.

发明人： Jared A. Gollob

IPC分类号： A61K31/7105 ,  A61K9/00 ,  A61K9/107 ,  A61K31/07 ,  A61K31/135 ,  A61K31/167 ,  A61K31/341 ,  A61K31/423 ,  A61K31/426 ,  A61K31/445 ,  A61K31/495 ,  A61K31/573 ,  A61K31/603 ,  A61P25/28 ,  C12N15/113

CPC分类号： A61K31/7105 ,  A61K9/0019 ,  A61K9/1075 ,  A61K31/07 ,  A61K31/135 ,  A61K31/167 ,  A61K31/341 ,  A61K31/423 ,  A61K31/426 ,  A61K31/445 ,  A61K31/495 ,  A61K31/573 ,  A61K31/603 ,  A61P25/28 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2320/31 ,  C12N2320/35

摘要： Disclosed herein are methods for treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof by administering an effective amount of a transthyretin (TTR)-inhibiting composition.